Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 18, Number 9—September 2012

Dispatch

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

Liesbet Van Heirstraeten, Samuel Coenen, Christine Lammens, Niel Hens, Herman Goossens, and Surbhi Malhotra-KumarComments to Author 
Author affiliations: University of Antwerp, Antwerp, Belgium (L. Van Heirstraeten, S. Coenen, C. Lammens, N. Hens, H. Goossens, S. Malhotra-Kumar); and University of Hasselt, Hasselt, Belgium (N. Hens)

Main Article

Figure 2

Predominant geno-emm-types that accounted for >5% of macrolide-resistant S. pyogenes, Belgium, 1999–2009.

Figure 2. . Predominant geno-emm-types that accounted for >5% of macrolide-resistant Streptococcus pyogenes, Belgium, 1999–2009.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO